Alzheimer's Disease

Lit-Fui Lau, Michael A. Brodney

$490.95 $392.41

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Springer-Verlag Berlin and Heidelberg GmbH & Co. K
30 November 2010

Cellular physiology; Pharmacology

Series: Topics in Medicinal Chemistry

Alzheimer’s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors).

This volume will first review existing cholinesterase inhibitors prescribed for AD patients followed by some target mechanisms with ongoing clinical trials. It offers a glimpse of what our future medicine cabinets may look like for AD patients. It also provides an interesting read on why and how current medicines for other indications could potentially be used to treat AD.

Edited by: Lit-Fui Lau, Michael A. Brodney
Imprint: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
Country of Publication: Germany
Edition: Softcover reprint of hardcover 1st ed. 2008
Volume: 2
Dimensions: Height: 235mm, Width: 155mm, Spine: 11mm
Weight: 454g
ISBN: 9783642093548
ISBN 10: 364209354X
Series: Topics in Medicinal Chemistry
Pages: 179
Publication Date: 30 November 2010
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview.- Cholinesterase Inhibitors.- Beyond Cholesterol: Statin Benefits in Alzheimer's Disease.- PPAR? Agonists for the Treatment of Alzheimer's Disease.- Metal Complexing Agents for the Treatment of Alzheimer's Disease.- GSK-3 Inhibitors for the Treatment of Alzheimer's Disease.

PRIZES to win! PROMOTIONS

Alzheimer's Disease

Lit-Fui Lau, Michael A. Brodney

$490.95 $392.41

Paperback

See Also

Contact Abbeys

Contact Galaxy

Contact Language

Contact Us

About ABBEY'S